Baidu
map

美国SITC发布,头颈部鳞状细胞癌免疫治疗专家共识

2019-11-10 蓝海贝 肿瘤资讯

美国癌症免疫治疗学会(SITC)于近日发布《头颈部鳞状细胞癌(HNSCC)免疫治疗专家共识》。临床上,提高复发或转移性头颈部鳞状细胞癌(R/M HNSCC)的治疗是一个迫在的亟需。而对于新兴免疫治疗,临床医师尚需要更多的认识,包括精准的患者选择、治疗序列、应答监测、不良事件管理,以及生物标记物检测等。为解决这样的需要,SITC制定此次的专家共识,共识编委包括专家医师、护士、科学家,以及患者权益维护

美国癌症免疫治疗学会(SITC)于近日发布《头颈部鳞状细胞癌(HNSCC)免疫治疗专家共识》。临床上,提高复发或转移性头颈部鳞状细胞癌(R/M HNSCC)的治疗是一个迫在的亟需。而对于新兴免疫治疗,临床医师尚需要更多的认识,包括精准的患者选择、治疗序列、应答监测、不良事件管理,以及生物标记物检测等。为解决这样的需要,SITC制定此次的专家共识,共识编委包括专家医师、护士、科学家,以及患者权益维护者就以上问题基于循证给予规范的临床指导。共识通过8个问题的形式给予推荐,这些指导意见反映免疫治疗应用于HNSCC的最新理念,希望临床医师合理应用而为HNSCC患者达到最大临床获益。

问题一:免疫治疗结合PD-1抑制剂如何应用于复发或转移性HNSCC?

一线治疗:

帕博利珠单抗适用于未接受过治疗的R/M HNSCC。

帕博利珠单抗单药治疗可用于R/M HNSCC以及PD-L1 CPS≥1患者的初始治疗。

帕博利珠单抗单药+化疗(铂类和氟尿嘧啶)可用于治疗未接受过治疗的、生物标志物不明确的R/M HNSCC患者。

二线治疗:

帕博利珠单抗或纳武单抗单药治疗应该应用于铂类难治性R/M HNSCC患者,包括接受铂类为基础化疗方案6个月内进展患者。

问题二:生物标志物检测在HNSCC患者的治疗中起什么作用?

指南委员会建议,不要使用MSI检测标准,即根据IHC染色PD-L1 ≥ 1% TPS或 ≥ 1 CPS为阳性。

当综合阳性评分(CPS)的HNSCC患者接受免疫治疗时,给予生物标记无检测。

问题三:HPV状态如何影响免疫治疗在HNSCC中的应用?

HPV状态(基于p16过度表达)应在治疗计划中,但不应影响为R/M HNSCC患者使用SOC免疫治疗的决策。

问题四:如何评估治疗应答,以及晚期HNSCC如何治疗?

起始治疗后1月内需有首次随访,用于确定免疫相关症状和不良反应(AE)

为继续观察免疫相关症状和AE,至少每月进行一次评估,如果患者不良反应剧烈需增加评估频次

首次随访后,应每3月进行一次患者评估(通过放射成像)以监测患者的应答迹象

经过治疗并接受6个月免疫治疗的维持治疗后,如果CR或者接近CR,则继续治疗至少2年或者治疗直到疾病进展或出现毒性反应

针对初次评估,请通过CT或PET-CT扫描技术为患者做一次基线检查

如果患者出现症状进展/临床恶化,停止治疗

如果在治疗早期观察到放射学进展,并且患者临床情况稳定,继续治疗第二次扫描确定病情恶化

如果在PD-1抑制剂治疗时或治疗后疾病进展:患者入组临床试验,请使用姑息放疗和/或化疗(紫杉烷)

问题五:应如何识别和处理HNSCC患者的免疫相关不良事件?

针对irAE < 3级,对于1级不良事件继续ICIs(某些神经、血液或心脏毒性事件除外);对于2级不良事件,停止IO治疗并密切监测门诊治疗情况(包括考虑使用口服类固醇激素)

针对irAE ≥ 3级,停止治疗,允许患者入院并服用类固醇激素

通过影像学检查和AST/ALT水平对甲状腺功能、颈部和气道行常规监测

对于甲状腺功能减退的患者,继续免疫治疗,给予左甲状腺素治疗,并每两月一次行甲状腺评估

如果发生巨快病变导致功能或器官损害:停止治疗

相比其他癌种而言,肺炎事件对于HNSCC接受免疫治疗患者不是太严重的问题

问题六:HNSCC患者中哪些患者不应该接受免疫治疗

不要根据年龄、肺癌转移、合并症,及自身免疫疾病等情况自行认为患者不适于抗PD-1单抗免疫治疗

患有丙型肝炎或者HIV+等免疫控制疾病的患者,CD4+ T细胞计数正常且正在接受抗逆转录病毒治疗,通常适合ICI治疗

问题七:免疫疗法在头颈癌罕见亚型的治疗中起什么作用?

对于转移性或局部晚期cSCC不适合行根治性手术或放疗患者,应使用cemiplimab

鼻咽癌患者不同于其他HNSCC患者。复发或转移性疾病患者建议入组临床试验(首要治疗选择);若患者无条件入组临床试验,铂类难治性鼻咽癌患者可以从PD-1/PD-L1单药治疗获益

问题八:如何在HNSCC患者的新型系统性联合治疗策略中结合免疫疗法?

出于提高患者应答率的考虑,所有共识编委中的临床工作者达成一致意见,对于疾病迅速进展患者推荐联合治疗(特别是:化疗+IO)。

从指南推荐来看,如何评估免疫应答,和如何处理免疫相关不良反应是临床最为关切的问题。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]
    2020-03-14 zhanglin3079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]
    2019-11-12 wshxjq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1845688, encodeId=87e218456880c, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Sep 20 22:12:00 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Mar 14 08:12:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978906, encodeId=b9ba19e890668, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Sep 03 21:12:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297700, encodeId=af63129e700ae, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491854, encodeId=16d3149185475, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589815, encodeId=7992158981517, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Tue Nov 12 04:12:00 CST 2019, time=2019-11-12, status=1, ipAttribution=)]

相关资讯

超声引导下星状神经节阻滞治疗头颈部带状疱疹爆发痛1例

患者,女,64岁,因“左侧耳垂、枕部疼痛4d伴左颈部红斑、疱疹1d”于2017年6月16日入院。既往有高血压病史,平时口服“氢氯噻嗪片”“螺内酯”“乐卡地平”,血压控制尚可。患者入院前3d因耳垂、枕部阵发性刀绞般疼痛来我科门诊就诊,当时行颈椎间盘CT示无明显异常,予加巴喷丁胶囊0.3g口服,3次/d,洛芬待因片200mg口服,3次/d,对症治疗,嘱门诊随诊。

头颈部鳞癌研究进展

美国临床肿瘤学会(ASCO)年会在芝加哥盛大开幕。作为全世界规模最大、学术水平最高、最具权威的临床肿瘤学术会议,大量最新研究进展在会上公布。头颈部鳞癌的临床治疗现状如何?有哪些最新的研究进展?来自同济大学附属东方医院的郭晔教授为您带来详细解读。

西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益

2018年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2018)于11月23-25日在新加坡举行。欧洲肿瘤内科学会(ESMO)成立于1975年,是欧洲领先的肿瘤内科学专业组织;2018 ESMO亚洲年会致力于使亚太地区肿瘤学专业人士与快速发展的肿瘤学科学与教育保持同步。在今年的ESMO亚洲年会上,来自上海同济大学附属东方医院的郭晔教授就复发/转移头颈鳞癌的III期CHANGE-2研究结果做了口头

RadioGraphics:头颈部肉芽肿性疾病

RadioGraphics:头颈部肉芽肿性疾病

JAHA:胸部、头颈部放射治疗后癌症患者他汀类药物使用与血管事件风险

由此可见,放射治疗后使用他汀类药物与卒中显著减少有关,并且趋向于显著减少心血管和脑血管事件。

头颈部侵袭性纤维瘤病1例

患者,男性,13岁,主诉因“右颈部无痛性肿物半年余”入院。入院查体:右侧颈上部皮肤稍隆起,皮温色泽正常,可触及一大小约3.5 cm×2.5 cm×3.0 cm肿物,前界位于胸锁乳突肌前缘前2.5 cm处,后界位于胸锁乳突肌前缘后1.0 cm处,上界达乳突,下界位于下颌下缘所在平面,表面光滑,活动度差,质硬,无触痛。入院前B超检查提示:右侧颈部皮下实质团块,待排良性间叶组织来源肿瘤。

Baidu
map
Baidu
map
Baidu
map